Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial

Simple item page
dc.contributor.authorNatukunda, Eva
dc.contributor.authorGaur, Aditya H.
dc.contributor.authorKosalaraksa, Pope
dc.contributor.authorBatra, Jagmohan
dc.contributor.authorRakhmanina, Natella
dc.contributor.authorPorter, Danielle
dc.contributor.authorRhee, Martin S.
dc.date.accessioned2022-03-07T13:51:00Z
dc.date.available2022-03-07T13:51:00Z
dc.date.issued2017
dc.description.abstractNo once-daily single-tablet regimen is available for HIV-infected children under 12 years. The single-tablet, fixed-dose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide is a once-daily, integrase strand transfer inhibitor-based regimen approved in the USA and European Union for individuals aged 12 years or older. In this study, we aimed to assess the pharmacokinetics, safety, and efficacy of this regimen in virologically suppressed, HIV-infected children. Methods In this single-arm, open-label trial, we enrolled virologically suppressed, HIV-infected children from five hospital clinics in Uganda, the USA, and Thailand. Eligible participants were aged 6–11 years, weighed 25 kg or more, had virological suppression (<50 copies of HIV-1 RNA per mL) on a stable regimen for at least 6 months, CD4 count of more than 100 cells per μL, and no history of resistance to elvitegravir, emtricitabine, tenofovir alafenamide, or tenofovir. All participants received the available fixed-dose oral formulation of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg once per day. Primary outcomes were the pharmacokinetic parameters area under the curve (AUC) concentration at the end of the dosing interval (AUCtau) for elvitegravir and the AUC from time zero to the last quantifiable concentration (AUClast) of tenofovir alafenamide, treatment-emergent serious adverse events, and all treatment-emergent adverse events. Results from baseline to week 24 are reported, unless specified otherwise. Primary and safety analyses included all enrolled participants who received one dose of study drug. This study is registered with ClinicalTrials.gov, number NCT01854775.en_US
dc.identifier.citationNatukunda, E., Gaur, A. H., Kosalaraksa, P., Batra, J., Rakhmanina, N., Porter, D., ... & Rhee, M. S. (2017). Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial. The Lancet Child & Adolescent Health, 1(1), 27-34.en_US
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S2352464217300093
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/2499
dc.language.isoenen_US
dc.publisherThe Lancet Child & Adolescent Healthen_US
dc.subjectpharmacokineticsen_US
dc.subjectHIV-infected childrenen_US
dc.subjectcobicistaten_US
dc.titleSafety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trialen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Safety--efficacy--and-pharmacokinetics-of-single-tablet-elvi_2017_The-Lancet.pdf
Size:
99.71 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences